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Literature on familial risk of carcinomas in situ (ciSs) is limited because many cancer registries do not 
collect information on CIS. In Sweden CISs are collected, and we used these data to analyze familial 
relative risks (RRs) for concordant (CIS-CIS) types of anogenital (cervical, other female and male genital 
and anal) and skin squamous cell CIS; additionally RRs were assessed between CIS types and between 
CIS and invasive forms. RRs were calculated for the offspring generations when family members were 
diagnosed CIS. Case numbers for CIS ranged from 330 in anal to 177,285 in cervical CIS. Significant 
concordant CIS-CIS RRs were 2.74 for female genital, 1.77 for cervical and 2.29 for SCC skin CISs. The 
CIS forms associated also with each other, except for cervical and skin CIS types. RRs for concordant 
ciS-invasive cancer associations were lower than ciS-ciS associations. cervical ciS associated with 
non-Hodgkin ciS which may suggest immune dysfunction as a contributing factors. the results for 
anogenital ciS types suggest that life style related human papilloma virus infections contributed to the 
observed familial associations. Lower risks for ciS-invasive cancer than ciS-ciS suggest that ciS and 
invasive cancers share only partially risk factors that underlie familial clustering.
Dysplasia is the earliest form of precancerous lesion and high-grade dysplasia is often synonymously referred to 
as carcinoma in situ (in situ cancer, CIS)1. CIS is a local accumulation of dysplastic cells. While CIS has not spread 
through its membranous borders, such as basement membrane, it may have the potential to do so and transform 
into cancer1,2. Because of cervical cancer screening programs, cervical CISs are very common and in many coun-
tries far outnumber invasive cervical cancers. Similarly, CIS for skin squamous cell (SCC) may outnumber the 
invasive SCCs in the skin3,4. Literature on CISs is limited because many cancer registries do not collect informa-
tion on them. In Sweden, notifications of CISs to the cancer registry are mandated similar to invasive cancer, and 
these are included in the Swedish Family-Cancer Database5.
Considering that CIS may be a precursor stage to malignant tumors the risk factors may be shared and for 
many environmental risk factors this appears to be the case2. Data on relative risks for breast, melanoma and 
some other CISs in families of concordant invasive cancer suggest that familial risk for CIS may be approximately 
equal to familial risks between the invasive forms of these cancers but data on concordant CISs are limited6–8. In 
the present study we assess familial risks of anogenital (cervical, other female and male genital and anal) cancers 
and skin cancers between CISs types and between CIS and invasive forms in order to test the hypothesis of shared 
familial risk factors to be extended to CIS, for which data are lacking in many cancer registries. Our previous 
study on familial CIS published in 2008 included far lower case numbers (e.g., only ¼ for male genital and 1/3 for 
female genital CIS); furthermore, it was limited to genital cancers and the present inclusion of upper aerodiges-
tive tract and colorectal cancers, melanoma and non-Hodgkin lymphoma is completely novel7. According to the 
International Classification of Diseases version 7, ‘other female genital cancers’ include the vulva and the vagina; 
‘other male genital cancers’ include the penis and the scrotum. These CISs and cancers share the SCC histology9. 
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Anogenital cancers are associated with human papillomavirus (HPV) infection, particularly related to the alpha 
genus of mucosal HPV types 16 and 1810,11. In skin SCC the beta genus HPVs may be playing a role but the evi-
dence has not been equivocal12,13. Another common denominator for these cancers is increasing risk in cases of 
immunodeficiency14–16. The risk is high in immunosuppressed organ transplant patients13–15. As immune defi-
ciency may be an important contributor even to cancers unrelated of infection, inclusion of non-Hodgkin lym-
phoma in the present study is relevant, as it is one of the most responsive cancers to immunosuppression14,16,17.
We use the Swedish Family-Cancer Database which is the largest family dataset in the world with a globally 
unique collection of CIS cases. We analyzed risks for both concordant (same cancer sites) and discordant (differ-
ent cancer sites) CISs and also including invasive cancers of the cervix, other female genitals and skin. In order to 
internally confirm the results we assess familial risks bi-directionally (in reverse order) as explained in Methods. 
For parent-offspring relationships the bidirectional analyses are essentially independent and, when agreeing, such 
data would provide support for true biological associations.
Results
The RRs were calculated to the 0–83 year old offspring generation for with 303,630 CIS cases were reported to 
the cancer registry (Supplementary Table 1). The largest numbers were for cervical (177,285, median diagnostic 
age 32 years) and skin (36,516, 68 years) CISs. The number of CISs in the anus was 330, in other female genital it 
was 3326 and in other male genital it was 1000. Considering also the parental generation the total CIS numbers 
reached 464,484.
Risks for concordant sites are shown in Table 1 for familial CIS-CIS and CIS-invasive cancer associations. RRs 
were calculated for daughters whose first-degree family members were diagnosed with concordant CIS or inva-
sive cancer. For cervical CIS, 20,188 familial patients were detected, resulting in RR of 1.77. The RR was 1.41 for 
invasive cervical cancer when a family member was diagnosed with cervical CIS; in reverse order the RR for cer-
vical CIS was 1.54 when a family was diagnosed with invasive cervical cancer. Note that the differences between 
CIS-CIS and CIS-invasive cancer analyses were significant, i.e., 95% confidence interval (CIs) did not overlap. For 
other female genital cancer only CIS-CIS association of RR 2.74 was significant. For skin SCC the RR for CIS-CIS 
association was 2.29 which was significantly higher than both of the CIS-invasive associations (1.92 and 2.07). For 
skin cancer male and female risks did not differ.
Discordant associations of cervical CIS are shown in Table 2. Bi-directional associations for cervical CIS can-
cer were found for other female genital CIS (1.59 and 1.79) and non-Hodgkin lymphoma (1.24 and 1.36). Among 
CIS-invasive pairs none were bi-directionally significant but the risk for female genital CIS was increased (1.42) 
when a family member had invasive cervical cancer; for upper aerodigestive tract CIS the RR was 1.57 when a 
family member had invasive cervical cancer. The bottom line shows the RRs for all CISs or invasive cancers com-
bined, with significant differences between respective CIS-CIS pairs and invasive-CIS pairs (1.35 vs. 1.12), and 
CIS-CIS pairs and CIS-invasive pairs (1.52 vs 1.31). When relevant, sex-specific risks were considered but none 
of the differences were significant (95%CIs overlapped).
In Table 3, discordant familial risks for other female genital CIS-CIS analyses showed increased bi-directional 
associations for cervical (RRs 1.79 and 1.59), skin (1.25 and 1.38), other male genital (2.82 and 3.79) and ovarian 
CIS (1.66 and 1.85). Among CIS-invasive pairs the only bidirectional association was noted with cervical cancer 
(1.48 and 1.19 which was significantly lower than 1.59 for the comparable CIS-CIS analysis). In the bottom line 
significant differences between respective combined CIS-CIS pairs and invasive-CIS pairs are shown (1.48 vs. 
1.15), similar to CIS-CIS pairs and CIS-invasive pairs (1.46 vs 1.13). Sex-specific risks were not significant.
Similar discordant analyses were carried out with CIS and invasive SCC skin cancer (Table 4). Bi-directional 
CIS-CIS associations were observed with skin CIS and other female genital (1.38 and 1.25), upper aerodiges-
tive tract (1.48 and 1.33), skin melanoma (1.63 and 1.59) CISs. The two latter ones showed also bi-directional 
associations in CIS-invasive pairs which however were of the same magnitude as the respective CIS-CIS associ-
ations. In contrast to the previous tables there was no significant difference between the combined CIS-CIS and 
CIS-invasive cancer RRs in the bottom line.
We carried out detailed analyses for two rare CIS types, other male genital and anal CIS but because of low 
case numbers no data are shown. The only significant bi-directional association was found with other female 
genital CIS; the RR for other male genital CIS was 3.79 (N = 6; 95%CI 1.70–8.46) when a family member was 
diagnosed with other female genital CIS, and it was 2.82 (N = 5; 95%CI 1.17–6.78) for female genital CIS when a 
family member was diagnosed with male genital CIS. For anal CIS-CIS pairs no bi-directional associations were 
Cancer site family 
member
RR for in situ cancer when family 
had the same in situ cancer
RR for invasive cancer when 
family had same in situ cancer
RR for in situ cancer when family 
had the same invasive cancer
Cases RR 95%CI Cases RR 95%CI Cases RR 95%CI
Cervix 20188 1.77 1.75–1.80 1127 1.41 1.33–1.50 2763 1.54 1.48–1.60
Other female genital 15 2.74 1.65–4.56 4 1.19 0.45–3.18 9 1.06 0.55–2.05
Skin squamous cell 3207 2.29 2.21–2.38 1620 1.92 1.83–2.02 2097 2.07 1.98–2.17
   Male 1612 2.30 2.19–2.42 951 1.96 1.83–2.10 1047 2.08 1.95–2.21
   Female 1595 2.28 2.17–2.40 669 1.87 1.73–2.03 1050 2.07 1.95–2.21
Table 1. Risks for in situ and invasive cancer when family members were diagnosed with concordant in situ or 
invasive cancer. RR = relative risk, 95%CI = 95% confidence interval, bold font indicates that the lower limit of 
95%CI does not include 1.00.
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Cancer site family member
RR for in situ cervical cancer when 
family member had in situ cancer
RR for in situ cancer when family 
member had in situ cervical cancer
RR for cervical cancer when 
family member had in situ cancer
RR for in situ cancer when family 
member had cervical cancer
Cases RR 95%CI Cases RR 95%CI Cases RR 95%CI Cases RR 95%CI
Other female genital 458 1.59 1.45–1.74 347 1.79 1.60–2.01 26 1.22 0.83–1.80 51 1.42 1.08–1.87
Skin, squamous cell 5966 0.93 0.91–0.96 1645 1.03 0.98–1.08 427 0.86 0.78–0.94 378 0.99 0.90–1.10
   Male NR 806 1.04 0.97–1.12 NR 198 1.06 0.92–1.21
   Female As above 839 1.01 0.95–1.09 As above 180 0.93 0.81–1.08
Upper aerodigestive tract 243 1.08 0.96–1.23 86 1.26 1.01–1.57 22 1.24 0.82–1.89 24 1.57 1.05–2.36
   Male NR 51 1.15 0.87–1.53 NR 13 1.30 0.75–2.26
   Female As above 35 1.44 1.02–2.04 As above 11 2.06 1.13–3.75
Other male genital 117 1.27 1.06–1.52 56 1.00 0.76–1.31 9 1.33 0.69–2.55 16 1.57 0.96–2.57
Colorectum 2223 0.97 0.93–1.02 819 0.99 0.92–1.06 181 1.03 0.89–1.19 185 0.98 0.85–1.13
   Male NR 476 1.02 0.93–1.12 NR 113 1.05 0.87–1.26
   Female As above 343 0.95 0.85–1.06 As above 72 0.89 0.70–1.12
Melanoma 1850 0.98 0.94–1.03 1283 1.09 1.03–1.15 122 0.93 0.78–1.11 219 0.97 0.85–1.11
   Male NR 541 1.02 0.93–1.11 NR 112 1.04 0.86–1.25
   Female As above 742 1.14 1.06–1.23 As above 107 0.90 0.74–1.09
Non-Hodgkin lymphoma 144 1.24 1.05–1.46 65 1.36 1.06–1.75 12 1.34 0.76–2.36 11 1.09 0.60–1.97
   Male NR 40 1.47 1.06–2.03 NR 5 0.85 0.35–2.05
   Female As above 25 1.22 0.81–1.83 As above 6 1.42 0.64–3.19
All (including cervix) 33607 1.35 1.33–1.37 26966 1.52 1.50–1.54 2090 1.12 1.07–1.18 4089 1.31 1.27–1.36
   Male NR 2474 1.05 1.01–1.09 NR 558 1.06 0.97–1.15
   Female As above 24492 1.58 1.56–1.60 As above 3531 1.36 1.31–1.40
Table 2. Risks for in situ and invasive cervical cancers in families of any in situ cancer, and risk for any in situ 
cancers in families of in situ and invasive cervical cancers. RR = relative risk, 95%CI = 95% confidence interval, 
bold font indicates that the lower limit of 95%CI does not include 1.00.
Cancer site family member
RR for in situ female genital cancer when 
family member had in situ cancer
RR for in situ cancer when family member 
had in situ female genital cancer
RR for female genital cancer when 
family member had in situ cancer
RR for in situ cancer when family 
member had female genital cancer
Cases RR 95%CI Cases RR 95%CI Cases RR 95%CI Cases RR 95%CI
Cervix 347 1.79 1.60–2.01 458 1.59 1.45–1.74 166 1.48 1.27–1.74 475 1.19 1.09–1.30
Skin, squamous cell 163 1.25 1.06–1.46 73 1.38 1.09–1.73 86 1.01 0.81–1.25 121 1.15 0.96–1.38
   Male NR 45 1.69 1.26–2.26 NR 52 1.00 0.76–1.31
   Female As above 28 1.06 0.73–1.53 As above 69 1.30 1.03–1.65
Upper aerodigestive tract 8 1.73 0.86–3.45 4 1.86 0.70–4.95 5 1.64 0.68–3.95 3 0.75 0.24–2.34
   Male NR 3 2.13 0.69–6.62 NR 3 1.16 0.37–3.60
   Female As above 1 1.33 0.19–9.46 As above 0 — —
Other male genital 5 2.82 1.17–6.78 6 3.79 1.70–8.46 2 1.83 0.46–7.34 4 1.59 0.60–4.26
Colorectum 39 0.87 0.63–1.19 25 0.95 0.64–1.41 27 0.92 0.63–1.35 43 0.85 0.63–1.15
   Male NR 14 1.69 1.26–2.26 NR 26 0.90 0.61–1.32
   Female As above 11 0.98 0.55–1.78 As above 17 0.79 0.49–1.27
Ovary 16 1.66 1.02–2.71 17 1.85 1.15–2.98 5 0.81 0.34–1.95 18 1.20 0.75–1.90
Melanoma 31 0.90 0.63–1.28 37 1.09 0.79–1.50 11 0.55 0.30–1.00 55 0.96 0.74–1.25
   Male NR 15 0.93 0.56–1.54 NR 32 1.14 0.81–1.62
   Female As above 22 1.23 0.81–1.86 As above 23 0.79 0.52–1.19
Non-Hodgkin lymphoma 2 0.89 0.22–3.54 2 1.39 0.35–5.56 0 — — 0 — —
   Male NR 1 1.19 0.17–8.45 0 — — 0 — —
   Female As above 1 1.67 0.24–11.91 0 — — 0 — —
All (including female 
genital) 668 1.48 1.36–1.62 697 1.46 1.35–1.57 330 1.15 1.03–1.30 839 1.13 1.05–1.21
   Male NR 102 1.34 1.11–1.63 NR 153 1.08 0.92–1.27
   Female As above 595 1.47 1.36–1.60 As above 686 1.14 1.05–1.22
Table 3. Risks for in situ and invasive other female genital cancers in families of any in situ cancer, and risk 
for any in situ cancers in families of in situ and invasive other female genital cancers. RR = relative risk, 
95%CI = 95% confidence interval, bold font indicates that the lower limit of 95%CI does not include 1.00
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found. Invasive anal cancer was associated with cervical CIS (RR 1.39; N = 131, 95%CI 1.16–1.66) and cervical 
CIS was associated with invasive anal cancer (RR 1.44; N = 327, 95%CI 1.29–1.60). Individual associations were 
found for anal CIS with male and female genital cancers and with non-Hodgkin lymphoma.
Discussion
In this systematic assessment of familial risks among CISs and between CIS and invasive anogenital and skin 
cancers several novel observations emerged. For three CISs we showed concordant bi-directional associations, 
including also associations between CIS and invasive cancer at the same sites. Additionally, we could define con-
sistent clustering between CIS at discordant sites and some were even supported by associations with invasive 
cancers. It is likely that the clustering can be explained at least in part by shared HPV infections and/or deficien-
cies in host immune response to infections7.
The concordant risks for CIS were 2.74 for female genitals, 1.77 for cervical and 2.29 for SCC skin CISs. 
Risks for concordant association between CIS and invasive cancers were consistently lower than for concordant 
CIS-CIS associations. For other female genital cancer, CIS-invasive cancer associations were not significant but 
the case numbers were low. For cervical and skin sites, CIS-CIS associations were significantly higher than the 
respective CIS-invasive cancer associations (1.41 and 1.54, the bi-directional risk for cervical CIS-invasive; 1.92 
and 2.07, the bi-directional risk for skin CIS-invasive). The low case numbers for other female genital cancers do 
not allow conclusions. On contrary, the large case numbers for cervical and skin CIS and invasive cancers suggest 
that the CIS and invasive types share familial risk factors to some degree but these appear not to be identical. 
These data appear consistent with the model that CIS may be a precursor of invasive cancer but the progressing 
clone of cells has acquired properties distinguishing them from the precursor population. For example, a clone of 
cells with specific HPV mutations will allow escape from host immune surveillance.
For comparison, in our recent analysis of invasive cancers, concordant other female genital cancers showed 
an RR of 2.72, almost exactly as the present CIC-CIS result of 2.74 (unpublished). According to the literature, 
Cancer site 
family member
RR for in situ skin squamous cell cancer 
when family member had in situ cancer
RR for in situ cancer when family member 
had in situ skin squamous cell cancer
RR for skin squamous cell cancer when 
family member had in situ cancer
RR for in situ cancer when family member 
had skin squamous cell cancer
Cases RR 95%CI Cases RR 95%CI Cases RR 95%CI Cases RR 95%CI
Cervix 1645 1.03 0.98–1.08 5966 0.93 0.91–0.96 1106 1.13 1.06–1.20 4201 0.98 0.95–1.02
   Male 806 1.04 0.97–1.12 NR 633 1.15 1.06–1.24 NR
   Female 839 1.01 0.95–1.09 As above 473 1.10 1.00–1.21 As above
Other female 
genital 73 1.38 1.09–1.73 163 1.25 1.06–1.46 46 1.42 1.06–1.90 102 1.13 0.93–1.38
   Male 45 1.69 1.26–2.26 NR 28 1.51 1.04–2.19 NR
   Female 28 1.06 0.73–1.53 As above 18 1.34 0.84–2.13 As above
Upper 
aerodigestive 
tract
74 1.48 1.18–1.86 72 1.33 1.05–1.69 44 1.49 1.11–2.00 55 1.44 1.10–1.89
   Male 35 1.45 1.04–2.01 46 1.31 0.98–1.77 26 1.56 1.06–2.29 24 0.96 0.64–1.45
   Female 39 1.52 1.11–2.08 26 1.35 0.91–2.00 18 1.40 0.88–2.23 31 2.33 1.62–3.35
Other male 
genital 25 1.44 0.97–2.13 37 0.97 0.70–1.35 14 1.35 0.80–2.29 26 1.00 0.68–1.48
   Male 16 1.93 1.18–3.15 As above 9 1.57 0.82–3.01 As above
   Female 9 0.99 0.52–1.90 NR 5 1.10 0.46–2.64 NR
Colorectum 482 1.03 0.94–1.13 651 0.93 0.86–1.00 296 1.06 0.94–1.18 427 0.86 0.78–0.95
   Male 227 0.98 0.86–1.11 352 0.87 0.78–0.97 172 1.07 0.92–1.25 249 0.88 0.77–0.99
   Female 255 1.08 0.95–1.22 299 1.00 0.89–1.13 124 1.04 0.87–1.24 178 0.84 0.72–0.97
Melanoma 517 1.63 1.49–1.78 1371 1.59 1.51–1.68 296 1.54 1.38–1.73 896 1.50 1.40–1.60
   Male 250 1.59 1.40–1.80 651 1.56 1.44–1.69 159 1.45 1.24–1.70 442 1.53 1.39–1.68
   Female 267 1.67 1.48–1.88 720 1.62 1.50–1.75 137 1.67 1.41–1.97 454 1.47 1.34–1.62
Non-Hodgkin 
lymphoma 28 1.17 0.81–1.70 40 1.09 0.79–1.50 19 1.33 0.85–2.09 25 0.97 0.65–1.44
   Male 12 1.03 0.59–1.82 26 1.20 0.81–1.79 11 1.36 0.75–2.45 13 0.85 0.49–1.48
   Female 16 1.31 0.80–2.14 14 0.93 0.54–1.58 8 1.30 0.65–2.61 12 1.14 0.64–2.03
All (including 
SCCa) 6424 1.50 1.46–1.55 13348 1.18 1.16–1.20 3677 1.41 1.36–1.46 9009 1.17 1.14–1.19
   Male 3180 1.51 1.45–1.57 3099 1.56 1.51–1.62 2121 1.43 1.36–1.50 2060 1.47 1.41–1.54
   Female 3244 1.50 1.44–1.56 10249 1.10 1.08–1.12 1556 1.39 1.32–1.47 6949 1.10 1.07–1.12
Table 4. Risks for in situ and invasive skin squamous cell cancers in families of any in situ cancer, and risk for 
any in situ cancers in families of in situ and invasive skin squamous cell cancers. SCCa = skin squamous cell 
cancer. RR = relative risk, 95%CI = 95% confidence interval, bold font indicates that the lower limit of 95%CI 
does not include 1.00.
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for concordant invasive cervical cancer familial associations have been 1.80 (between sisters) and 1.74 (between 
daughter and mother)7. For invasive skin SCC concordant familial association has been reported as 2.0618.
Cervical CIS associated with female genital and anal CIS (and to some degree with invasive types) which 
would be consistent with susceptibility to HPV infections. Cervical CIS was also consistently associated with 
non-Hodgkin lymphoma. Based on cancers arising in immunosuppressed patients, non-Hodgkin lymphoma is 
considered one of the hallmarks of dysfunctional immune system14,15. Thus HPV susceptibility may be assisted by 
weak immune resistance shared by family members. HPV infections are usually sexually transmitted which would 
be unlikely to explain familial risk, and non-sexual transmissions from an infected mother during pregnancy or 
early childhood are supposed to be rare19,20. We assume that shared life-style with many sexual partners may the 
explanation to the observed familial risks. In our previous study on women who had children with different men 
in Sweden we observed increased risks for many life-style related cancers, including cervical, other female genital, 
upper aerodigestive tract, anal, liver, and lung cancers21. The results would thus suggest a gene-environment asso-
ciation in which immune dysfunction would be the genetic partner and HPV the environmental actor.
It is noteworthy that there was no association between cervical and skin CISs for which the infective HPV 
genus is suggested to be different and ultraviolet irradiation is the risk factor for skin SCC only12. The case num-
bers were large and the lacking of risk was consistent in Tables 2 and 4. Yet skin CIS was associated with female 
genital and upper aerodigestive tract CISs, both of which are known targets of mucosal HPV types12. The expla-
nation remains unclear but the diagnostic age for skin CIS (68 years) was more than doubled for that of cervical 
CIS (32 years). A curious bi-directional association was noted between ovarian CIS and other female genital CIS. 
Previous data on the possible role of HPV in ovarian cancer is inconclusive, based on small positive and negative 
studies12.
In conclusion, the results showed that anogenital CISs showed concordant familial associations and discord-
ant associations between each other, most likely related to a life-style with risk of HPV infections. For cervical 
CIS association with non-Hodgkin lymphoma CIS suggested contribution by immune dysfunction. Familial risks 
were lower for concordant CIS-invasive cancer associations than for CIS-CIS associations which suggests only a 
partial overlap of risk factors for the CIS and invasive cancers.
Methods
Database and cancer ascertainment. We used the update of the Swedish Family-Cancer Database 
which covered CIS and invasive cancers from 1958 through 2015 and family links over a century22. The Database 
includes 16 million individuals, covering the offspring generations born between 1932 and 2015 and their biolog-
ical parents (the parental generation) in some 4 million nuclear families. Siblings could be identified only in the 
offspring generation which reached a maximal age of 83 years in 2015.
Coverage of cytologically or histologically verified incident cancers is considered to be over 90% complete on 
account of compulsory nationwide registration by clinicians and pathologists23. Cancer identification was based 
on the four-digit code according to the 7th revisions of the International Classification of Diseases (ICD-7).
Statistical analysis. Relative risks (RRs) were used to estimate cancer risks and each table contained three or 
four different but related analyses. RRs were calculated for the offspring generation. The first pair of data included 
CIS-CIS risks: (1) risk for CIS X when family members (parents of siblings) were diagnosed with any defined CIS, 
and (2) risk for any defined CIS and risk when family members were diagnosed with CIS X. For concordant CISs 
(Table 1) the results for (1) and (2) were identical and the data were not repeated. The second pair of data included 
invasive cancer-CIS: (3) risk for cancer X in offspring when family members were diagnosed with any defined 
CIS, and 4) risk of any defined CIS when family members were diagnosed with cancer X. Analyses (1) and (2) as 
well as (3) and (4) are independent for discordant cancers, and positive results in both analyses provided strong 
support for a true association. The differences between analyses (1) and (3), or (2) and (4) differ in that invasive 
cancer at the same site is replaced by CIS, and is being used to compare RRs between CIS-CIS and CIS-invasive 
associations.
Follow-up was started for each offspring at birth, immigration or January 1st, 1958, whichever came latest. 
Follow-up was terminated on diagnosis of CIS or invasive cancer, death, emigration, or the closing date of the 
study, which was December 31st, 2015. Termination of follow-up at diagnosis of the first tumor is a standard prac-
tice in cancer epidemiology to guard against biases such as surveillance bias24. The reference rates were generated 
for the same CIS or invasive cancer for those who did not have the relevant family history. Poisson regression 
modeling was employed to estimate RRs and corresponding 95% confidence intervals (CI). Potential confound-
ers, including sex, age group (5-year bands), period (5-year bands), socioeconomic status (blue-collar worker, 
white-collar worker, farmer, private, professional, or other/unspecified) and residential area (large cities, South 
Sweden, North Sweden, or unspecified) were added to the model as covariates.
All statistical analyses were done with the SAS version 9.4. Data are shown in tables for anogenital (cer-
vix, other female and male genital, upper aerodigestive tract) and skin CISs, for common CIS types (breast and 
colorectum) and for any bi-directional associations (ovary in Table 3).
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